PapersFlow Research Brief
Tuberous Sclerosis Complex Research
Research Guide
What is Tuberous Sclerosis Complex Research?
Tuberous Sclerosis Complex Research is the scientific investigation of the genetic disorder Tuberous Sclerosis Complex (TSC), caused by mutations in TSC1 or TSC2 genes encoding hamartin and tuberin proteins, focusing on its multisystem manifestations, mTOR signaling dysregulation, neurological effects like epilepsy and cognitive impairment, and therapeutic interventions such as mTOR inhibitors.
Tuberous Sclerosis Complex Research encompasses 27,044 published works examining genetic mutations in TSC1 and TSC2, protein functions of hamartin and tuberin, and associated conditions including Lymphangioleiomyomatosis and Angiomyolipoma. Studies detail neurological manifestations such as epilepsy and cognitive impairment alongside diagnostic criteria updates. Research highlights the TSC1/TSC2 complex's role in suppressing mTOR signaling, with key mechanisms identified through phosphorylation and GTPase regulation.
Topic Hierarchy
Research Sub-Topics
TSC1 and TSC2 Genetic Mutations
This sub-topic examines the identification, functional consequences, and clinical spectrum of mutations in the TSC1 (hamartin) and TSC2 (tuberin) genes underlying Tuberous Sclerosis Complex. Researchers study genotype-phenotype correlations, mosaicism, and novel variants through genetic sequencing and patient registries.
mTOR Signaling Pathway in TSC
This sub-topic investigates the TSC-hamartin/tuberin complex's regulation of Rheb and mTORC1 signaling, including phosphorylation events and downstream effectors. Researchers explore dysregulation mechanisms and therapeutic inhibition using rapalogs like everolimus.
Neurological Manifestations of TSC
This sub-topic covers cortical tubers, subependymal nodules, seizures, and autism spectrum disorders in TSC patients. Researchers analyze neuroimaging, epileptogenesis, and neurodevelopmental outcomes using EEG and MRI studies.
Lymphangioleiomyomatosis in TSC
This sub-topic focuses on pulmonary LAM in female TSC patients, including cyst formation, lung function decline, and VEGF-D biomarkers. Researchers study TSC2-mutant smooth muscle cell proliferation and sirolimus efficacy in clinical cohorts.
TSC Diagnostic Criteria and Consensus
This sub-topic reviews updates to clinical and genetic diagnostic guidelines from international consensus conferences. Researchers validate imaging, genetic testing, and minor criteria for early detection in sporadic and familial cases.
Why It Matters
Tuberous Sclerosis Complex Research informs clinical management of a multisystem disorder affecting children and adults through defined diagnostic criteria and targeted therapies. "Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference" by Northrup and Krueger et al. (2013) provides updated recommendations for diagnosis, enabling precise identification of TSC features. In renal applications, temsirolimus, an mTOR inhibitor, improved overall survival compared to interferon alfa in patients with metastatic renal-cell carcinoma and poor prognosis, as shown in "Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma" by Hudes et al. (2007), demonstrating TSC-related mTOR pathway targeting in cancer treatment. "The Tuberous Sclerosis Complex" by Crino, Nathanson, and Henske (2006) outlines pathogenesis and management, supporting interventions for epilepsy and tumors.
Reading Guide
Where to Start
"The Tuberous Sclerosis Complex" by Crino, Nathanson, and Henske (2006) provides a foundational overview of TSC pathogenesis, genetics, and management suitable for beginners.
Key Papers Explained
"Identification of the Tuberous Sclerosis Gene TSC1 on Chromosome 9q34" by van Slegtenhorst et al. (1997) and "Identification and characterization of the tuberous sclerosis gene on chromosome 16" (1993) established the TSC1 and TSC2 genes. Inoki et al. (2002) in "TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling" and Inoki et al. (2003) in "Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling" detailed molecular mechanisms. Manning et al. (2002) in "Identification of the Tuberous Sclerosis Complex-2 Tumor Suppressor Gene Product Tuberin as a Target of the Phosphoinositide 3-Kinase/Akt Pathway" connected tuberin to Akt signaling. Crino et al. (2006) synthesized clinical implications, while Northrup and Krueger et al. (2013) updated diagnostics.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research continues to explore mTOR dysregulation details from Inoki et al. (2002, 2003) and Manning et al. (2002) in therapeutic contexts like Hudes et al. (2007) temsirolimus trials. No recent preprints or news available indicate focus remains on established mechanisms and criteria from Northrup and Krueger et al. (2013).
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | The 2015 World Health Organization Classification of Lung Tumors | 2015 | Journal of Thoracic On... | 4.4K | ✕ |
| 2 | Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell... | 2007 | New England Journal of... | 3.6K | ✕ |
| 3 | TSC2 is phosphorylated and inhibited by Akt and suppresses mTO... | 2002 | Nature Cell Biology | 3.0K | ✕ |
| 4 | Rheb GTPase is a direct target of TSC2 GAP activity and regula... | 2003 | Genes & Development | 1.9K | ✓ |
| 5 | The Tuberous Sclerosis Complex | 2006 | New England Journal of... | 1.8K | ✕ |
| 6 | Identification and characterization of the tuberous sclerosis ... | 1993 | Cell | 1.7K | ✕ |
| 7 | Identification of the Tuberous Sclerosis Gene <i>TSC1</i> on C... | 1997 | Science | 1.7K | ✕ |
| 8 | Identification of the Tuberous Sclerosis Complex-2 Tumor Suppr... | 2002 | Molecular Cell | 1.5K | ✓ |
| 9 | Pten is essential for embryonic development and tumour suppres... | 1998 | Nature Genetics | 1.5K | ✕ |
| 10 | Tuberous Sclerosis Complex Diagnostic Criteria Update: Recomme... | 2013 | Pediatric Neurology | 1.5K | ✓ |
Frequently Asked Questions
What genes cause Tuberous Sclerosis Complex?
Tuberous Sclerosis Complex results from mutations in TSC1 on chromosome 9q34, encoding hamartin, or TSC2 on chromosome 16, encoding tuberin. "Identification of the Tuberous Sclerosis Gene TSC1 on Chromosome 9q34" by van Slegtenhorst et al. (1997) identified TSC1 from a 900-kilobase region. "Identification and characterization of the tuberous sclerosis gene on chromosome 16" (1993) characterized the TSC2 gene.
How does the TSC complex regulate mTOR signaling?
The TSC1/TSC2 complex inhibits mTOR signaling by acting as a GAP for Rheb GTPase. "Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling" by Inoki et al. (2003) showed TSC2 targets Rheb to suppress S6K and 4EBP1 phosphorylation. "TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling" by Inoki et al. (2002) demonstrated TSC2 phosphorylation by Akt inhibits its function.
What are the diagnostic criteria for TSC?
Diagnostic criteria for TSC were updated in 2012 to include genetic and clinical features. "Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference" by Northrup and Krueger et al. (2013) provides consensus recommendations. These criteria aid in identifying hamartomas and neurological manifestations.
What is the role of tuberin in TSC?
Tuberin, the TSC2 gene product, functions in the TSC complex to suppress mTOR signaling and acts as a target of the PI3K/Akt pathway. "Identification of the Tuberous Sclerosis Complex-2 Tumor Suppressor Gene Product Tuberin as a Target of the Phosphoinositide 3-Kinase/Akt Pathway" by Manning et al. (2002) identified tuberin as phosphorylated by Akt. "The Tuberous Sclerosis Complex" by Crino et al. (2006) describes its role in pathogenesis.
How do mTOR inhibitors relate to TSC research?
mTOR inhibitors target the dysregulated pathway in TSC caused by TSC1/TSC2 mutations. "Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma" by Hudes et al. (2007) showed temsirolimus improved survival in poor-prognosis renal-cell carcinoma, relevant to TSC-associated Angiomyolipoma. TSC research links this to hamartin/tuberin suppression of mTOR.
Open Research Questions
- ? How do specific TSC1 and TSC2 mutations differentially affect mTOR pathway inhibition in neuronal versus renal tissues?
- ? What are the long-term neurological outcomes of mTOR inhibitor treatments in TSC patients with epilepsy?
- ? How does TSC2 GAP activity on Rheb interact with other GTPases in hamartoma formation?
- ? What molecular mechanisms link TSC mutations to cognitive impairment beyond mTOR signaling?
- ? How can updated diagnostic criteria incorporate novel imaging or biomarker findings for early TSC detection?
Recent Trends
The field comprises 27,044 works with no specified 5-year growth rate.
High-citation papers from 1993-2013, such as van Slegtenhorst et al. with 1657 citations for TSC1 and Inoki et al. (2002) with 3019 for TSC2-Akt-mTOR, dominate.
1997No recent preprints or news in the last 12 months available.
Research Tuberous Sclerosis Complex Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Tuberous Sclerosis Complex Research with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers